C4 Therapeutics, Inc. (CCCC)
Nasdaq: CCCC · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Feb 26, 2026 | Feb 27, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 | Mar 11, 2021 | · |
| Revenue | 35,947 | 35,584 | 20,756 | 31,096 | 45,785 | · | · |
| Research and development | 104,240 | 110,637 | 117,706 | 117,841 | 94,665 | 78,440 | 48,059 |
| General and administrative | 36,196 | 42,124 | 42,081 | 42,789 | 33,254 | 15,204 | 8,774 |
| Total operating expenses | 151,169 | 155,198 | 159,787 | 160,630 | 127,919 | 93,644 | 56,833 |
| Operating income | -115,222 | -119,614 | -139,031 | -129,534 | -82,134 | -60,449 | -35,452 |
| Total non-operating income (expense) | 10,349 | 14,429 | 7,818 | 1,359 | -1,758 | -6,512 | 2,157 |
| Income before income taxes | -104,873 | -105,185 | -131,213 | -128,175 | -83,892 | -66,961 | -33,295 |
| Income tax expense | 121 | 131 | 1,280 | 0 | 0 | -626 | 804 |
| Net income including non-controlling interests | · | · | · | · | -83,892 | -66,335 | -34,099 |
| Net income | -104,994 | -105,316 | -132,493 | -128,175 | -83,892 | -66,335 | -34,099 |
| Preferred dividends | · | · | · | · | · | · | 8,468 |
| Net income to common shareholders | · | · | · | · | -83,892 | -66,335 | -42,567 |
| Earnings per share, basic | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 | -31.03 |
| Earnings per share, diluted | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.82 | -5.83 | -31.03 |
| Weighted average shares, basic | 82,894,459 | 69,372,993 | 49,640,505 | 48,861,665 | 46,041,733 | · | · |
| Weighted average shares, diluted | 82,894,459 | 69,372,993 | 49,640,505 | 48,861,665 | 46,041,733 | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 46,041,733 | 11,370,328 | 1,371,905 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted